Drug combination for advanced lung cancer with hormone-like cell changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two oral and intravenous drugs – surufatinib and tislelizumab – for people with advanced lung cancer that shows certain hormone-like cell traits. The goal is to see if this pair can shrink or slow the cancer better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic lung cancer (stage IIIB or IV) that can’t be removed with surgery.
- Your tumor must show certain markers that are common in cells that produce hormones, but it is not a typical neuroendocrine tumor.
- You have at least one tumor that can be measured on scans, and you are generally able to do most daily activities (ECOG 0-1).
- You are eligible to receive immunotherapy as your first treatment, or you have already had one standard chemotherapy that stopped working.
- Your urine protein level is low or, if higher, it’s still within a safe range.
- You have not previously received drugs that block blood vessel growth (anti-VEGF) or immunotherapy (anti-PD-1/PD-L1).
- You do not have uncontrolled high blood pressure, active ulcers, bleeding problems, or a history of other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two drugs—an immunotherapy called tislelizumab and an experimental antibody-drug conjugate called SYS6010—for people with advanced non-small cell lung cancer who have already tried immunotherapy and their cancer continued to grow. The goal is to see if this combination can help control the cancer better.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of three drugs (surufatinib, serplulimab, and standard chemotherapy) as a first treatment for advanced solid tumors that have neuroendocrine differentiation. The goal is to see if this combination helps control the cancer better than standard therapy alone.
This study tests a combination of two medications (surufatinib and serplulimab) for advanced solid tumors that have stopped responding to standard treatment and show special neuroendocrine markers. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.